<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02911688</url>
  </required_header>
  <id_info>
    <org_study_id>15-1938</org_study_id>
    <secondary_id>4R01ES023349-04</secondary_id>
    <nct_id>NCT02911688</nct_id>
  </id_info>
  <brief_title>Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure</brief_title>
  <acronym>Gammoz</acronym>
  <official_title>Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Environmental Health Sciences (NIEHS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of 1200mg gamma tocopherol (yT), a form of vitamin E, given daily on the
      response of the airway in mild asthmatics after exposure to ozone (O3)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allergic asthma (AA) is the most commonly encountered respiratory disease in children and
      adults in the United States and is a leading cause of morbidity worldwide. Among the most
      disruptive expressions of disease in AA is acute asthma exacerbation. The CDC lists ambient
      air pollutants and environmental tobacco smoke as among the most common triggers for acute
      asthma exacerbation. Ozone (O3) is the most commonly encountered ambient air pollutant in the
      US.

      Increased oxidative stress and decreased antioxidant capability have been observed in
      asthmatics. These pollutants are pro-inflammatory and are associated with increased oxidative
      stress, which would exacerbate reactive oxygen and reactive nitrogen species (ROS and
      RNS)-induced injury in asthmatics. O3 injures epithelial cells, releasing secondary mediators
      which activate inflammatory cells, in part by ligation of TLR4, the primary receptor for LPS.
      TLR4 activation of inflammatory cells activates NF-kB and induces oxidative stress. O3 and
      LPS has been associated with exacerbation of asthma, and we have reported that O3 and LPS
      augments allergic airway inflammation in allergic asthmatics (AA). Development of
      interventions to mitigate these responses will greatly decrease disease morbidity. Given the
      role that oxidants play in the pathophysiology of asthma exacerbation, defects in antioxidant
      levels would increase risk for acute asthma exacerbation. Nutritional deficiencies in vitamin
      E, ascorbate and selenium have been linked to asthma severity, and asthmatics have decreased
      antioxidant levels in airway fluid. It has been shown that vitamins C and E are decreased in
      airway fluids of asthmatics. Additionally, genetic factors may increase risk for oxidant
      induced exacerbation of asthma. Many investigators have reported that persons who are
      homozygous for the null polymorphism of the Glutathione-S-Transferase Mu1 (GSTM1) gene and
      unable to produce GSTM1 protein (the GSTM1 null genotype) have increased risk of acute
      pollutant-induced exacerbation of asthma. This lab has shown in healthy volunteers that the
      GSTM1 null genotype is associated with increased inflammatory response to O3, with no impact
      on the nociceptive response to this pollutant.

      Other researchers have shown that the GSTM1 null genotype is associated with increased
      response to secondhand tobacco smoke, diesel exhaust, and other particulate matter
      components. Romieu et al demonstrated that children with asthma in Mexico City were had
      increases susceptibility to O3-induced exacerbations if they had the GSTM1 null genotype.
      This group also found that GSTM1 null AAs selectively benefited from antioxidant
      intervention. The GSTM1 null genotype is found in 20-40% of the population, and may be
      overrepresented in allergic populations. Taken together, these observations show that the
      sizable GSTM1 null population is at risk for pollutant-induced airway disease, and that
      antioxidant intervention targeting the action of ROS and RNS will benefit asthmatics and
      especially GSTM1 null asthmatics.

      A non-exclusive list of proposed antioxidants includes radical scavengers such as ascorbate,
      a-tocopherol (aT), y-tocopherol (yT) or inducers of NRF2, which activate NRF2 with subsequent
      broad upregulation of acute phase II and antioxidant proteins. These agents are available in
      naturally occurring foods and as nutritional supplements. A number of animal, cell culture
      and epidemiological studies support the idea that antioxidant supplementation is useful in
      allergic airway disease. However, despite these studies and widespread public and scientific
      enthusiasm regarding use of such agents in asthmatics, there are scant human data to support
      or refute the use of such interventions for either acute or chronic allergic airways disease.

      Gamma tocopherol has both radical scavenging and anti-inflammatory actions which may play
      important roles in decreasing pollutant-induced and allergic injury to the airway. Like other
      isoforms of vitamin E, yT is a potent ROS scavenger and is also a powerful nucleophile that
      traps electrophiles such as peroxynitite in lipophilic compartments. One mechanism by which
      y-T is cytoprotective is scavenging of RNS at the un-substituted C-5 position on the
      hydroxy-chroman ring of y-T to form 5-NO-y-tocopherol (5-NO-yT). Overall, vitamin E provides
      general protection of DNA, lipids and proteins from radical stress. An example of such
      protection is shown in rodent studies of prostate cancer in which intake of yT is associated
      with decreased DNA methylation of CpG rich regions of the NRF2. NRF2 is a master regulator of
      numerous cytoprotective antioxidant enzymes.

      Supplementation with yT also prevents protein nitration and attenuates loss of plasma vitamin
      C in plasma in a rodent peritonitis model of inflammation. Our group has also shown that yT
      inhibits COX-2 and 5-LO in LPS-stimulated macrophages and IL-1b stimulated epithelial cells.
      These actions are mediated primarily by the yT metabolite 2, 7,
      8-trimethyl-2S-(.-carboxyethyl)-6-hydroxychroman (y-CEHC) which requires hydroxylation of the
      y-methyl group of yT by cytochrome P450 (CYP450). In carrageenan- induced inflammation in
      male Wistar rats, yT decreases prostaglandin (PGE2) and leukotriene (LTB4) production,
      suggesting that LO-mediated production of leukotrienes may also be inhibited by yT.
      Tocopherols, including yT, also modulate gene expression of a number of inflammatory genes.
      Thus, yT and other tocopherols decrease production of a number of pro-inflammatory cytokines
      at the transcriptional level.

      In animals, it has also been shown that gamma tocopherol reduces baseline eosinophilia in the
      airway. In our early phase I studies of gamma tocopherol-enriched mixed tocopherols (gT-mT)
      we have shown that gT-mT inhibits monocyte induced cytokine production, decreases baseline
      nitrosative stress, and inhibits LPS eosinophil and neutrophil influx in healthy volunteers.

      SUMMARY:

      There is widespread opinion that antioxidant nutrients like gamma tocopherol ( yT, a form of
      Vitamin E) are an untapped and inexpensive intervention for environmentally triggered acute
      asthma. However, there is a crucial gap in evidence-based support of such interventions in
      asthma. A lack of coordinated research assessing specific antioxidant regimens from
      preclinical, phase I and phase II studies impedes development of phase III antioxidant trials
      in asthmatic populations. It is also unclear which physiological endpoints are most relevant
      in such studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in sputum %PMNs</measure>
    <time_frame>8 hours after final dose of study drug</time_frame>
    <description>After supplementation with either active or placebo, subjects will undergo O3 exposure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Safflower oil, taken in 2 capsules every 12 hours for a total of 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gamma tocopherol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gamma tocopherol 1400 mg, taken as 2 700 mg capsules every 12 hours for a total of 4 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gamma tocopherol</intervention_name>
    <description>The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after Î³T dosing.</description>
    <arm_group_label>gamma tocopherol</arm_group_label>
    <other_name>Vitamin E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Safflower oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-45 of both genders

          2. Negative pregnancy test for females who are not s/p hysterectomy with oopherectomy

          3. History of episodic wheezing, chest tightness, or shortness of breath consistent with
             asthma, or physician diagnosed asthma.

          4. Positive methacholine test. A positive test is defined as a provocative concentration
             of methacholine of 10 mg/ml or less producing a 15% fall in FEV1 (PC20 methacholine)
             by the method used in a separate screening protocol or a PRE and POST bronchodilator
             challenge used to determine reversible lung function. Reversibility is confirmed with
             a 10-12% increase in FEV1 15 minutes after inhaling 4 puffs of albuterol with a
             spacer. Reversibility is used in the same separate screening protocol; or a clinical
             history of asthma after the age of 6.

          5. FEV1 of at least 80% of predicted and FEV1/FVC ratio of at least .70 (without use of
             bronchodilating medications for 12 hours or long acting beta agonists for 24 hours),
             consistent with lung function of persons with no more than mild episodic or mild
             persistent asthma.

          6. Allergic sensitization to at least one of the following allergen preparations: (House
             Dust Mite f, House dust mite p, Cockroach, Tree mix, Grass Mix, Weed Mix, Mold Mix 1,
             Mold Mix 2, Rat, Mouse, Guinea Pig, Rabbit, Cat or Dog) confirmed by positive
             immediate skin test response; or a clinical history consistent with seasonal or
             perennial allergy symptoms.

          7. Symptom Score (this will be submitted as an attachment) no greater than 20 (out of a
             possible 60) for total symptom score with a value no greater than 3 for any one score.
             No more than one score may be greater or equal than 3.

          8. subjects must be willing to avoid caffeine for 12 hours prior to all visits.
             Methacholine challenge and allergy skin testing are performed as part of IRB 98-0799,
             which a subject must complete in order to be considered for this protocol.

          9. for subjects who are prescribed inhaled corticosteroids. These volunteers must be able
             to come off of the ICS for 2 weeks without increased symptoms or increased need for
             beta agonist rescue medication prior to screening and throughout the course of the
             study.

        Exclusion Criteria:

          1. Any chronic medical condition considered by the PI as a contraindication to the
             exposure study including significant cardiovascular disease, diabetes, chronic renal
             disease, chronic thyroid disease, history of chronic infections/immunodeficiency,
             history of tuberculosis

          2. Physician directed emergency treatment for an asthma exacerbation within the preceding
             3 months

          3. Moderate or Severe asthma

          4. Exacerbation of asthma more than 2x/week which would be characteristic of a person of
             moderate or severe persistent asthma as outlined in the current NHLBI guidelines for
             diagnosis and management of asthma.

          5. Daily requirement for albuterol due to asthma symptoms (cough, wheeze, chest
             tightness) which would be characteristic of a person of moderate or severe persistent
             asthma as outlined in the current NHLBI guidelines for diagnosis and management of
             asthma. (Not to include prophylactic use of albuterol prior to exercise).

          6. Viral upper respiratory tract infection within 4 weeks of challenge.

          7. Any acute infection requiring antibiotics within 4 weeks of exposure or fever of
             unknown origin within 4 weeks of challenge.

          8. Severe asthma

          9. Mental illness or history of drug or alcohol abuse that, in the opinion of the
             investigator, would interfere with the participant's ability to comply with study
             requirements.

         10. Medications which may impact the results of the O3 exposure, interfere with any other
             medications potentially used in the study (to include systemic steroids, beta
             antagonists, non-steroidal anti-inflammatory agents)

         11. Any history of smoking in the year prior to study enrollment; lifetime smoking history
             &gt; 10 pack years

         12. Nighttime symptoms of cough or wheeze greater than 1x/week at baseline (not during a
             clearly recognized viral induced asthma exacerbation) which would be characteristic of
             a person of moderate or severe persistent asthma as outlined in the current NHLBI
             guidelines for diagnosis and management of asthma

         13. Allergy/sensitivity to study drugs, or their formulations.

         14. Known hypersensitivity to methacholine or to other parasympathomimetic agents

         15. History of intubation for asthma

         16. Unwillingness to use reliable contraception if sexually active (IUD, birth control
             pills/patch, condoms).

         17. Abnormal PT or aPTT values at screening or during the treatment period. Normal values
             will be those published by the clinical lab (Labcorp, INC).

         18. Any bleeding disorder

         19. Orthopedic conditions which would prevent the volunteer from performing moderate
             exercise on a treadmill.

         20. Radiation exposure history will be collected. Subjects whose exposure history within
             the past twelve months would cause them to exceed their annual limits will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B Peden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carole A Robinette, MS</last_name>
    <phone>919-966-5638</phone>
    <email>carole_robinette@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martha A Almond, RCP</last_name>
    <phone>919-966-0759</phone>
    <email>martha_almond@med.unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Environmental Medicine, Asthma and Lung Biology</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>gamma-Tocopherol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

